NanoBiotix - Converge study Part 1 data presented at ESTRO 2026 for stage 3 unresectable NSCLC treated with intratumoral JNJ-1900 (NBTXR3) radioenhancer plus concurrent chemoradiotherapy and durvalumab; early results show feasible, safe injection and promising initial efficacy in 7 patients: ORR 85.7% (6/7), CRR 57.1% (4/7), DCR 100.0% (7/7), with no progressive disease and response deepening over time suggesting potential durability.
- Converge study Part 1 data presented at ESTRO 2026 for stage 3 unresectable NSCLC treated with intratumoral JNJ-1900 (NBTXR3) radioenhancer plus concurrent chemoradiotherapy and durvalumab; early results show feasible, safe injection and promising initial efficacy in 7 patients: ORR 85.7% (6/7), CRR 57.1% (4/7), DCR 100.0% (7/7), with no progressive disease and response deepening over time suggesting potential durability.